Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase

Journal of Virology

Volumn 76, Issue 12, 2002, Pages 6083-6092

  Van Rompay, Koen K A ^a   Matthews, Tim B ^a   Higgins, Joanne ^a   Canfield, Don R ^a   Tarara, Ross P ^a   Wainberg, Mark A ^a   Schinazi, Raymond F ^a   Pedersen, Niels C ^a   North, Thomas W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; LAMIVUDINE; METHIONINE; RNA DIRECTED DNA POLYMERASE; VALINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; FITNESS; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS PATHOGENESIS; VIRUS VIRULENCE;

ANIMALS; ANIMALS, NEWBORN; ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; LAMIVUDINE; MACACA MULATTA; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRULENCE; VIRUS REPLICATION;

EID: 0036113511     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.12.6083-6092.2002     Document Type: Article

References (71)

1. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
2. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1 specific non-nucleoside reverse transcriptase inhibitors
3. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1
4. Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors
5. Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2′, 3′-dideoxy-3′-thiacytidine
6. Rapid and sensitive method for detection of hepatitis C virus RNA by using silica particles
7. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate
8. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
9. Resisting resistance: Maximizing the durability of antiretroviral therapy
10. Primary lamivudine resistance in acute/early human immunodeficiency virus infection
11. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
12. Primary HIV infection: In vivo fitness of pretherapy resistant mutants and potential for secondary spread of HIV from semen
13. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
14. Identification of highly attenuated mutants of simian immunodeficiency virus
15. The role of herpes simplex virus type 1 thymidine kinase in pathogenesis
16. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter
17. The AIDS epidemic
18. Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP
19. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: The relative roles of drift and selection
20. Anti-human immunodeficiency virus activities of the β-L enantiomer of 2′,3′-dideoxycytidine and its 5-fluoro derivative in vitro
21. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis
22. Human immunodeficiency virus fitness in vivo: Calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase
23. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction
24. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
25. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
26. Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: Sustained reduction in viral markers
27. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′,3′-dideoxy-3′-thiacytidine
28. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine
29. Importance of the nef gene for maintenance of high virus loads and for development of AIDS
30. Initial appearance of the 184e variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase
31. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients
32. Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus
33. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
34. Real-time Taqman PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA
35. Lamivudine in children with human immunodeficiency virus infection: A phase I/II study
36. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance
37. Viral determinants of simian immunodeficiency virus (SIV) virulence in rhesus macaques assessed by using attenuated and pathogenic molecular clones of SIVmac
38. Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques
39. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
40. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro
41. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring
42. Effects of reverse-transcriptase mutations M184V and E89G on simian immunodeficiency virus in rhesus monkeys
43. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo
44. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection
45. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type fitness and disease progression
46. Clinical significance of drug resistance in human immunodeficiency virus
47. Prototype trial design for rapid dose selection of antiretroviral drugs: An example using emtricitabine (Coviracil)
48. Activation of PAK by HIV and SIV nef: Importance for AIDS in SIV-infected rhesus macaques
49. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
50. Rapid changes in human immunodeficiency virus type RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)
51. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation
52. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071
53. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
54. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: A phase I study
55. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection
56. 9-[2-(phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection infant rhesus macaques
57. 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA
58. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques
59. A zidovudine-resistant simian immunodeficiency virus mutant with a Q51M mutation in reverse transcriptase causes AIDS in newborn macaques
60. Administration of 9-[2-(phosphonomethoxy)propyl] adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques
61. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: Oral 3′-azido-3′-deoxythymidine prevents SIV infection
62. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection
63. Prophylactic and therapeutic benefits of short-term 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA
64. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS
65. Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection
66. Enhanced fidelity of 3TC-selected mutant HIV-reverse transcriptase
67. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA
68. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors